Tag Archives: pharmacy

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA – JAMA Network

  1. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA JAMA Network
  2. Study finds popular weight loss drugs can lead to serious problems | 9 News Australia 9 News Australia
  3. Researchers link popular weight loss drugs to serious digestive problems for ‘hundreds of thousands’ worldwide CNN
  4. GLP-1 Agonists, Like Ozempic and Wegovy, Have Risk of Gut Issues: Study BioSpace
  5. GLP-1 Agonists Linked to Higher Risk for GI Complications Medscape
  6. View Full Coverage on Google News

Read original article here

Philadelphia police release videos of suspects wanted for looting at P.C. Richard & Son, South Philly Pharmacy – WPVI-TV

  1. Philadelphia police release videos of suspects wanted for looting at P.C. Richard & Son, South Philly Pharmacy WPVI-TV
  2. Alleged Philadelphia looter ‘Meatball’ who livestreamed downtown chaos, ‘traumatized’ after release on bail Fox News
  3. SHOCKING VIDEO: Looters raid, destroy Target store in Philadelphia 6abc Philadelphia
  4. Police are searching for dozens of suspects still wanted for this week’s lootings in Philadelphia NBC 10 Philadelphia
  5. A night of looting underscores the need for a balanced approach to public safety in Philadelphia | Editorial The Philadelphia Inquirer
  6. View Full Coverage on Google News

Read original article here

Vegetarian Diet May Significantly Improve Cardiometabolic Outcomes in Those with High Cardiovascular Risk – Pharmacy Times

  1. Vegetarian Diet May Significantly Improve Cardiometabolic Outcomes in Those with High Cardiovascular Risk Pharmacy Times
  2. Vegetarian dietary patterns may reduce cardiovascular disease risk Medical News Today
  3. Meta-analysis finds vegetarian diets effective in lowering cholesterol, glucose and weight Medical Xpress
  4. Vegetarian Diet May Augment Effects of Optimal Drug Therapy in Patients at High Risk of CVD Patient Care Online
  5. A Vegetarian Diet May Help Improve Your Cholesterol, Blood Sugar Levels and Lead to Weight Loss Healthline
  6. View Full Coverage on Google News

Read original article here

Study: Donanemab Significantly Reduces Cognitive, Functional Decline Associated With Alzheimer Disease – Pharmacy Times

  1. Study: Donanemab Significantly Reduces Cognitive, Functional Decline Associated With Alzheimer Disease Pharmacy Times
  2. Alzheimer’s patient: New ‘miracle’ drug has ‘given me my life back’ New York Post
  3. New Alzheimer’s treatment: Donanemab drug seen as turning point in fight against disease FRANCE 24 English
  4. Eli Lilly says FDA approval of Alzheimer’s drug donanemab could come later this year Fox Business
  5. More developments being made in Alzheimer’s research WBAL-TV 11 Baltimore
  6. View Full Coverage on Google News

Read original article here

CDC Announces Recommendation for RSV Vaccine in Older Adults – Pharmacy Times

  1. CDC Announces Recommendation for RSV Vaccine in Older Adults Pharmacy Times
  2. CDC approves use of new vaccines for RSV in older adults KSL.com
  3. Older Americans can get RSV vaccine this fall after consulting their doctor, CDC says San Francisco Chronicle
  4. RSV infection responsible for up to 10000 deaths among older adults per year in the US: CDC | TheHealthSi TheHealthSite
  5. Statement from HHS Secretary Xavier Becerra on CDC’s Historic Recommendation Allowing Older and Immunocompromised Adults to Receive the RSV Vaccine HHS.gov
  6. View Full Coverage on Google News

Read original article here

CVS, Walmart and Walgreens to reduce pharmacy hours as staffing challenges persist

CVS cutting down, adjusting pharmacy hours in two-thirds of stores


CVS cutting down, adjusting pharmacy hours in two-thirds of stores

00:37

CVS and Walmart are reducing their pharmacy operating hours across the U.S. to improve employees’ work-life balance as the chains continue to struggle with staffing shortages in the wake of the COVID-19 pandemic.

CVS said it will be “adjusting hours in select stores” come spring, as part of a periodic review of “operating hours to make sure we’re open during peak customer demand.” The move will affect around two-thirds of the company’s approximately 9,000 retail pharmacies beginning in March, a company spokesperson said in a statement to CBS MoneyWatch. 

CVS, which is the largest pharmacy chain in the U.S. by revenue, said it’s making the schedule changes in order to “ensure our pharmacy teams are available to serve patients when they’re most needed,” a CVS spokesperson said. “If a pharmacy is closed, a patient can visit any open CVS Pharmacy location for assistance with their immediate prescription needs,” the spokesperson added.

Walmart reduces hours, raises pay

Walmart also said it’s cutting hours at its pharmacy locations nationwide to improve “work-life balance” for its associates. 

Walmart pharmacies will be open from 9 a.m. to 7 p.m. Monday through Friday. Previously they were open until 9 p.m. on weekdays. 

“Walmart is committed to helping our associates live better. Walmart has a strong and incredible pharmacy team, and we are making this change to not only enhance their work-life balance but also to maintain the best level of service for our customers,” Walmart said in a statement to CBS MoneyWatch. 

Walmart said it’s making the schedule change based on feedback from pharmacy staff and customers. 

“By positioning our teams in the hours where our customers say they want to visit our pharmacy, we are better able to deliver excellent customer service and support our associates as they continue to serve their communities every day,” Walmart said. 

In mid-June, Walmart announced higher wages for more than 36,000 pharmacy technicians, raising their average hourly pay to more than $20.

Prior to the pandemic, pharmacists and pharmacy technicians outnumbered opportunities for employment, according to Michael Hogue, dean of the Loma Linda University School of Pharmacy. 

As the COVID-19 vaccines first began to be rolled out in 2021, regional and national pharmacy chains were clamoring for qualified workers to support the massive public health campaign. Job opportunities for pharmacy students soared.

Walgreens hires more pharmacists, raises pay

A spokesperson for the Walgreens pharmacy chain, the second largest in the U.S., also said it has had to adjust pharmacy hours over the past 12-plus months due to staffing challenges. 

Walgreens added that it has hired thousands of pharmacists as well as increased pharmacy workers’ pay to address ongoing staffing issues. It said the efforts are working and the issues are subsiding. 

“We have seen positive staffing trends for the past several months as we work to return more stores to normal operating hours,” Walgreens said. 

Pharmacies aggressively hired pharmacists and pharmacy technicians starting in February 2021, when COVID-19 vaccines were first made available to the general public, to accelerate efforts to inoculate as many people as possible. Pharmacist job postings surged and drugstore chains offered hefty signing bonuses of up to $20,000.

Read original article here

CVS, Walmart to Cut Pharmacy Hours as Staffing Squeeze Continues

CVS, the largest U.S. drugstore chain by revenue, plans in March to cut or shift hours at about two-thirds of its roughly 9,000 U.S. locations. Walmart plans to reduce pharmacy hours by closing at 7 p.m. instead of 9 p.m. at most of its roughly 4,600 stores by March.

Walgreens Boots Alliance Inc.

previously said it was operating thousands of stores on reduced hours because of staffing shortages. Combined, the three chains operate some 24,000 retail pharmacies across the U.S. 

Walmart last year raised pay for pharmacy technicians.



Photo:

Ryan David Brown for The Wall Street Journal

Earlier in the pandemic, CVS and Walgreens struggled to meet demand for Covid shots and vaccines. The chains cut hours and, in some cases, closed pharmacies for entire weekends. Walmart, which sells a wider variety of goods, cut overall store hours, in part, to cope with Covid-related labor shortages and make time to restock empty shelves as demand for basics such as toilet paper surged.  

CVS, in a recent notice to field leaders, said most of its reduced hours will be during times when there is low patient demand or when a store has only one pharmacist on site, which the company said is a “top pain point,” for its pharmacists. 

CVS said in a statement it periodically reviews pharmacy operating hours as part of the normal course of business to ensure stores are open during high-demand times. “By adjusting hours in select stores this spring, we ensure our pharmacy teams are available to serve patients when they’re most needed,” the company said, adding that customers who encounter a closed pharmacy can seek help at a nearby location. 

At Walmart, the shorter hours offer pharmacy workers a better work-life balance and best serve customers in the hours they are most likely to visit the pharmacy, said a company spokeswoman. “This change is a direct result of feedback from our pharmacy associates and listening to our customers,” she said. Some Walmart pharmacies already close before 9 p.m., which will become standard across the country after the change.

An online community message board for Holliston, Mass., a small town about 30 miles outside Boston, was populated with messages last month from locals venting about the unpredictable hours of the CVS in town, said resident Audra Friend, who does digital communications for a nonprofit. Ms. Friend said she struggled for a week in November to refill a prescription for a rescue inhaler at the store because the pharmacy was sporadically closed.

“I would go in, and there was a note on the door saying, ‘Sorry, pharmacy closed,’” said Ms. Friend, who switched her prescriptions to a 24-hour CVS about 5 miles away. She said it would be better to have consistently shorter hours if that meant fewer unexpected closures. “At least that way we’re not just showing up at CVS to find out the pharmacist isn’t there,” she said.

A CVS spokeswoman said that in recent weeks the Holliston store has had no unexpected closures.

The drugstore chains have been working to stop an exodus of pharmacy staff by offering such perks as bonuses, higher pay and guaranteed lunch breaks. Pharmacists were already in short supply before the pandemic, and consumer demand for Covid-19 shots and tests put additional strains on pharmacy operations. Walgreens recently said staffing problems persist and remain a drag on revenue. 

Retail pharmacies, which benefited from a bump in sales and profits during the pandemic, are now reworking their business models as demand for Covid tests and vaccines decline and generic-drug sales generate smaller profits.

CVS and Walgreens are closing hundreds of U.S. stores and launching new healthcare offerings as they try to transform themselves into providers of a range of medical services, from diagnostic testing to primary care.  

This past summer, Walgreens was offering bonuses up to $75,000 to attract pharmacists, while CVS is working to develop a system in which pharmacists could perform more tasks remotely. The median annual pay for pharmacists was nearly $129,000 in 2021, according to Labor Department data, which also projected slower-than-average employment growth in the profession through 2031. 

In the past year, the chains have poured hundreds of millions of dollars into recruiting more pharmacists and technicians but staffing up has proven difficult. Pharmacists remain overworked, pharmacy-chain executives have acknowledged, and fewer people are attending pharmacy schools. The number of pharmacy-school applicants has dropped by more than one-third from its peak a decade ago, according to the Pharmacy College Application Service, a centralized pharmacy-school application service.

Meanwhile, many pharmacists who aren’t quitting the field are leaving drugstores to work in hospitals or with other employers. 

Walmart raised wages for U.S. pharmacy technicians in the past year, bringing average pay to more than $20 an hour. Walmart said it planned to raise the minimum wage for all U.S. hourly workers in its stores and warehouses to $14 next month, from $12.

CVS and Walgreens last year raised their minimum wages to $15 an hour.

Write to Sharon Terlep at sharon.terlep@wsj.com and Sarah Nassauer at Sarah.Nassauer@wsj.com

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here

CVS plans to sell Omnicare long-term care pharmacy business, saying it is ‘no longer a strategic asset’

CVS Health President and CEO Karen Lynch

Woonsocket, RI-based CVS Health plans to sell its long-term care pharmacy business, Cincinnati-based Omnicare, reporting a $2.5 billion loss related to it in the third quarter, the company announced Wednesday.

“We continue to evaluate our portfolio strategically and are making decisions around assets that don’t fit into our portfolio strategically. Omnicare is a good example of that,” President and CEO Karen Lynch said Wednesday morning on the company’s third-quarter earnings call.

“The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business,” CVS said in a filing with the Securities and Exchange Commission on Wednesday, made in conjunction with the call.

Omnicare serves senior living communities, skilled nursing facilities and Programs of All-Inclusive Care for the Elderly (PACE).

For accounting purposes, Omnicare “met the criteria for held-for-sale accounting and the net assets were accounted for as assets held for sale,” the company reported Wednesday. “The carrying value of the LTC business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the third quarter of 2022.”

In the third quarter, according to CVS, the company recorded a $2.5 billion pretax loss on assets held for sale to write down the company’s long-term care business in the current year, which partially was offset by the absence of a $431 million goodwill impairment charge on the remaining goodwill of the Omnicare unit recorded in the prior year.

2015 acquisition

CVS acquired Omnicare in 2015 for $10.4 billion plus the assumption of $2.3 billion in Omnicare debt, according to published sources. At the time, then-CEO Larry Merlo said that the purchase gave the retail pharmacy giant “access into a new pharmacy dispensing channel.”

Rumors of a possible Omnicare sale circulated in August 2020, when a CVS spokeswoman told McKnight’s Senior Living that it would be consolidating positions within the long-term care business. Some put the number of positions at stake at more than 700, although CVS did not confirm a specific amount.

“The healthcare industry is evolving as patients and clients change how they interact with service providers and as payer programs evolve,” Shelly Bendit, a senior communications consultant with CVS Health, said at the time. “We regularly evaluate all of our businesses to ensure that we are positioned to best serve our customers while running our operations as efficiently as possible.”

CVS had not publicly expressed an intention to leave the long-term care business at that point, but a few months earlier, in January 2020, Merlo had described the company’s experience with Omnicare as “disappointing.” In remarks during a J.P. Morgan Healthcare Conference session, he also noted that the skilled nursing sector was “challenged” and that people’s desire to convalesce at home was continuing to affect demand for long-term institutional pharmacy services.

“We continue to see the opportunity in the growth of assisted and independent living, and that’s where our focus remains,” he said at the time, according to a transcript.

On an August 2020 earnings call, CVS executives noted that the COVID-19 pandemic had “substantially affected” Omnicare and the company’s long-term care presence overall.

“As you look at the industry challenges, we’ve seen admissions down about 20% and some facilities continuing to not accept new patients but not be shut down per se,” CVS Health Vice President and Chief Financial Officer Eva Boratto said at the time.

Lynch joined CVS as its new CEO in February 2021. Early this year, effective July 1, Ahmed Hassan was appointed president of Omnicare, having joined CVS Health in 2015. At the time, he called Omnicare “a rock-solid company filled with passionate long-term care experts.”

Costing the company money

But long-term care-related legal actions also have cost the company money.

In May 2020, for instance, Omnicare agreed to pay a $15.3 million civil penalty to settle allegations that it violated federal law by allowing opioids and other controlled substances to be dispensed without a valid prescription.

Omnicare denied the allegations but settled the lawsuit “to avoid the expense and uncertainty of potential litigation,” a company spokesman told McKnight’s Senior Living at the time.

Separately and not specific to long-term care, on Wednesday, CVS announced an agreement in principle to pay approximately $5.2 billion over 10 years, beginning in 2023, to settle what Lynch described as “substantially all opioid lawsuits and claims against CVS Health by states, political subdivisions and tribes.”

That outcome, she said, “is in the best interest of all parties and one that will help put a decades-old issue behind us as we continue to focus on delivering a superior health experience for the millions of consumers who rely on us.”

On the Wednesday earnings call, Lynch also noted that CVS had signed an agreement to sell online benefits enrollment/administration system creator bswift (to global investment firm Francisco Partners), a business she also described as “nonstrategic.” CVS had acquired the company as part of Aetna buy in 2018.

“As we divest assets, we will continue to invest in areas aligned with our strategy with a disciplined approach to capital allocation,” she said. The company also recently sold health savings account business Payflex (to Millennium Trust) and part of its Aetna international business, Lynch noted.

Not all sales

But it’s not all divestitures for the company.

In September, CVS announced that it was buying Signify Health, a company focused on “health risk assessments, value-based care and provider enablement,” for $8 billion.

“This acquisition will enhance our connection to consumers in the home and enables providers to better address patient needs as we execute our vision to redefine the healthcare experience. In addition, this combination will strengthen our ability to expand and develop new product offerings in a multi-payer approach,” Lynch said at the time.

Wednesday, she said that the transaction is expected to close in the first half of next year, and she also hinted at future home-related spending.

“We said we wanted to be in the home. We’ll make investments around that,” Lynch said, echoing comments she made in September at the Morgan Stanley Global Healthcare Conference.

$3B+ revenues expected for segment in 2022

Despite the potential sale of Omnicare, CVS’ retail/long-term care segment is expected to see more than $3 billion in revenues in 2022 due to COVID-19, Executive Vice President and Chief Financial Officer Shawn Guertin said.

“It is not prudent to anticipate a similar level of COVID-based revenues going forward,” however, he said, “and we expect that the economics on vaccines and diagnostic testing will change following the expiration of the public health emergency, which we project will happen in the early part of the first quarter of 2023.”

Overall, the retail/long-term care segment, which includes CVS Pharmacy locations serving the general public in addition to Omnicare, “continues to outperform expectations,” Lynch said, with revenues of $2.67 billion in the quarter representing growth of almost 7% versus the prior year, with $1.4 billion in adjusted operating income, according to executives.

“Performance in both the front store and pharmacy was strong,” Lynch said, noting that front store sales were up approximately 4% and that demand for COVID vaccines and over-the-counter tests, as well as cough, cold and flu products, remains high.

The number of prescriptions filled, she said, grew 1.8% year-over-year in the third quarter, or 3.6% if COVID vaccines are excluded.

“This growth helped propel our retail pharmacy business to another quarter of year-over-year market share gains, extending a trend that started in the first quarter of 2020,” Lynch said.

In addition to its retail/long-term care segment, CVS also has a healthcare benefits segment and a pharmacy services segment.

Overall, Lynch characterized the quarter as “outstanding.”

“During the third quarter, we grew revenue by 10% versus the prior year to over $81 billion and grew adjusted operating income by nearly 4% over the prior year to $4.2 billion,” she said. “Adjusted earnings per share in the quarter was $2.09, an increase of over 6% from the prior year.”

Learn more about the company’s third-quarter performance on the CVS corporate website.

Read original article here

How Pharmacy Work Stopped Being So Great

If any group of workers might have expected their pay to rise last year, it would arguably have been pharmacists. With many drugstores dispensing coronavirus tests and vaccines while filling hundreds of prescriptions each day, working as a pharmacist became a sleep-deprived, lunch-skipping frenzy — one in which ornery customers did not hesitate to vent their frustrations over the inevitable backups and bottlenecks.

“I was stressed all day long about giving immunizations,” said Amanda Poole, who left her job as a pharmacist at a CVS in Tuscaloosa, Ala., in June. “I’d look at patients and say to them, ‘I’d love to fill your prescriptions today, but there’s no way I can.’”

Yet pay for pharmacists, who typically spend six or seven years after high school working toward their professional degree, fell nearly 5 percent last year after adjusting for inflation. Dr. Poole said her pay, about $65 per hour, did not increase in more than four years — first at an independent pharmacy, then at CVS.

For many Americans, one of the pandemic’s few bright spots has been wage growth, with pay rising rapidly for those near the bottom and those at the top. But a broad swath of workers in between has lagged behind.

In the two years after February 2020, income for those between the middle and the top tenth of earners grew less than half as quickly as income for those in the top 1 percent, according to data collected by a team of economists at the University of California, Berkeley.

The gap is part of a long-term trend made worse by a slowdown in pay gains for middle- and upper-middle-income workers in the 2000s. “If you’re going to a hedge fund or investment bank or a tech company, you’ve done enormously well,” said Lawrence Katz, a labor economist at Harvard. Typical college graduates, he said, “have not done that great.”

The stagnation appears to have moved up the income ladder in the last few years, even touching those in the top 10 percent.

In some cases, the explanation may be a temporary factor, like inflation. But pharmacists illustrate how slow wage growth can point to a longer-term shift that renders once sought-after jobs less rewarding financially and emotionally.

In 2018, Suzanne Wommack moved from western Missouri, where she had worked for several years as a pharmacist at a Hy-Vee supermarket, to the eastern part of the state, where she and her husband had relatives. The job she landed as a Walgreens pharmacy manager in Hannibal, roughly an hour-and-a-half outside St. Louis, paid her about $62 per hour — nearly $6 below her previous hourly wage, though regional pay differences helped to explain the drop.

More striking was how few pharmacists Walgreens appeared to employ. At Hy-Vee, Dr. Wommack worked with one or two other pharmacists for most of the day. At Walgreens, the volume of business was similar, she said, but she was almost always the only pharmacist on duty during her shift, which often ran from 8 a.m. until the pharmacy closed at 8 p.m.

“I had to quit breastfeeding within a month of starting because I could never pump or eat enough to sustain milk,” Dr. Wommack, who had given birth to her third child a few months before taking the new job, said in an email. She said she later began taking anti-anxiety medication and antidepressants to cope with stress at work.

The job market Dr. Wommack encountered was a stark reversal from a decade earlier. In the 2000s, wages in the profession surged as the country faced a pharmacist shortage driven by an aging population and a rise in chronic conditions.

Universities ramped up enrollment in pharmacy programs, leading to a fivefold increase in graduates — to roughly 10,000 new pharmacists — in the decade that ended in 2007. (Pharmacists typically take two or three years of college-level prerequisites before earning a four-year professional degree.)

But by the 2010s, the market for pharmacists was cooling thanks to some of the same factors that have weighed on other middle-class professions. Large chains such as Walgreens and CVS were buying up competitors and adjacent businesses like health insurers.

This consolidation generated large fees for workers at the top of the income ladder — financiers and corporate lawyers — but slowed the growth of retail outlets where pharmacists could find employment. After striking a deal in 2017 to acquire roughly 2,000 Rite Aid stores, Walgreens shut down more than 500 locations. It closed a few hundred more over the next three years.

Automation has further reduced demand for workers — many pharmacists now spend far less time processing insurance claims because software does it for them.

Pharmacies also faced external challenges. To hold down the cost of prescription drugs, insurance companies and employers rely on so-called pharmacy benefit managers to negotiate discounts with drugmakers and pharmacies. Consolidation among benefit managers gave them more leverage over pharmacies to drive prices lower. (CVS merged with a large benefits manager in 2007.)

Big drugstore chains often responded by trying to rein in labor costs, according to William Doucette, a professor of pharmacy practice at the University of Iowa. Several pharmacists who worked at Walgreens and CVS said the formulas their companies used to allocate labor resulted in low levels of staffing that were extremely difficult to increase.

According to documents provided by a former CVS pharmacist, managers are motivated by bonuses to stay within these aggressive targets. CVS said it made staffing decisions to ensure “the safe and accurate filling of prescriptions.”

The day that Dr. Poole began seriously reconsidering her CVS job in Tuscaloosa came in May 2021 when, nearly eight months pregnant, she fainted at work.

The loss of consciousness was nothing serious in itself — she and the baby were unharmed, and an adjustment to her blood-pressure medication solved the problem. Much more alarming to her was what the episode said about working conditions: Despite the additional responsibilities of the pandemic, like coronavirus vaccines and catering to Covid-19 patients, there was no co-worker around to notice that she had hit the deck.

“No one knew I was passed out until a customer, said, ‘Um, is anyone back in the pharmacy?’” Dr. Poole recalled. “They found me on the ground.”

In most cases, an industry without enough workers to meet customer demand would simply hire more, or at least raise wages to attract them.

Yet, according to the Bureau of Labor Statistics, neither of those things happened last year. The number of pharmacists employed in the United States dropped about 1 percent from 2020 to 2021. On balance, employers did not raise wages — in fact, median pay fell slightly, even without adjusting for inflation.

While this data is not yet available for 2022, a contract signed in March by a union of Chicago-area Walgreens pharmacists reflected a similar approach. It provided maximum base pay of $64.50 per hour, the same as the previous contract, but lowered the starting wage from $58 per hour to $49.55 per hour by September. (Like many retail pharmacists, the union members also receive bonuses.)

CVS and Walgreens said they had made hiring pharmacists a priority during the pandemic — CVS said it employed nearly 6 percent more pharmacists today than it did in early 2020; Walgreens declined to provide a figure. CVS said its compensation was “very competitive” for pharmacists, and Walgreens cited “ongoing phased wage increases”; both chains have offered signing bonuses to recruit pharmacists. The Chicago union said Walgreens had recently offered to raise pay for about one-quarter of its lowest-paid members.

To explain the wage stagnation of upper-middle-class workers during the pandemic, some economists have suggested that affluent workers are willing to accept lower wage growth for the ability to work from home. Dr. Katz, of Harvard, said the wages of many affluent workers might simply be slower to adjust to inflation than the wages of lower-paid workers.

But Marshall Steinbaum, an economist at the University of Utah, said the fact that upper-middle-class workers were not able to claim a larger share of last year’s exceptionally high corporate profits “speaks to the disempowerment of workers at all levels of status.”

Late last year, CVS announced that it planned to shut 900 stores, or nearly 10 percent of its locations, by 2024. Steven Valiquette, an equity analyst at Barclays, suggested the move was partly intended to hold down the wage bill for pharmacists and other personnel. “It was well timed to take labor pressure off the franchise,” Mr. Valiquette said in an interview. (CVS said it retained 95 percent of the employees from the stores it closed this year.)

When drugstores have added personnel during the pandemic, they have often added pharmacy technicians, who help fill prescriptions, instead of pharmacists, effectively replacing costly workers with less costly ones.

In late 2020, Sarah Knolhoff, then a pharmacist at a Walgreens in Rockford, Ill., received an email from management announcing that it was planning to hire several pharmacists in her area to help administer Covid vaccines. But the positions never materialized. The company later announced that a change in state regulations would allow pharmacy technicians to administer shots. “They expected the techs to transition into that role,” Dr. Knolhoff said.

Overall, the industry added more than 20,000 technicians — an increase of about 5 percent — from 2020 to 2021. In that time, prescription volume increased roughly the same percentage, according to data from Barclays.

The effective replacement of higher-paid workers with lower-paid workers has also occurred in other sectors, such as higher education. But at drugstores, where pharmacists must sign off on every prescription, this shift has left little margin for error.

In August 2020, Dr. Wommack, the Walgreens pharmacist in Missouri, got Covid. A colleague covered her first two days out but couldn’t cover the third, at which point the store simply closed because there was no backup plan.

Several pharmacists said they were especially concerned that understaffing had put patients at risk, given the potentially deadly consequences of mix-ups. “It was so mentally taxing,” said Dr. Poole, the Tuscaloosa pharmacist. “Every day, I was like: I hope I don’t kill anyone.”

Asked about safety and staffing, CVS and Walgreens said they had made changes, like automating routine tasks, to help pharmacists focus on the most important aspects of their jobs.

Many pharmacists contacted for this article quit rather than face this persistent dread, often taking lower-paying positions.

Still, none had regrets about the decision to leave. “I was 4,000 pounds lighter the moment I sent my resignation email in,” said Dr. Wommack, who left the company in May 2021 and now works at a small community hospital.

As for the medication she had taken for depression and anxiety while at Walgreens, she said, “Shortly after I stopped working there, I stopped taking those pills.”



Read original article here

India needs to fill China gaps to become the “pharmacy of the world”

India has embarked on an ambitious plan to cut dependence on China for key raw materials as it seeks to become self-sufficient in its quest to be the “pharmacy of the world.”

Varun Singh Bhati | Eyeem | Getty Images

India has embarked on an ambitious plan to cut dependence on China for key raw materials as it seeks to become self-sufficient in its quest to be the “pharmacy of the world.”

Already the world’s third-largest manufacturer of medicines by volume, India has one of the lowest manufacturing costs globally. About one in three pills consumed in the U.S. and one in four in the U.K. are made in India.

However, India’s $42 billion pharmaceutical sector is heavily dependent on China for key active pharmaceutical ingredients or API — chemicals that are responsible for the therapeutic effect of drugs. 

According to a government report, India imports about 68% of its APIs from China as it’s a cheaper option than manufacturing them domestically.

However, an estimate by the Trade Promotion Council, a government supported organization, puts the figure of API dependence on China at about 85%. Another independent study carried out in 2021 points out that while India’s API imports from China are at nearly 70%, its dependence on China for “certain life-saving antibiotics” is around 90%. Some drugs that are highly dependent on Chinese APIs include penicillin, cephalosporins and azithromycin, the report said.

That may be starting to change.

Under a government scheme launched two years ago, 35 APIs began to be produced at 32 plants across India in March. This is expected to reduce dependence on China by up to 35% before the end of the decade, according to an estimate by ratings firm ICRA Limited, the Indian affiliate of Moody’s.

India emerged as a large supplier of Covid-19 vaccines, supplying to 75 countries, including Indonesia, where a medical officer injects the vaccine AstraZeneca into a recipient in Bintan island on July 2, 2021.

(Photo credit Yuli Seperi / Sijori images/Future Publishing via Getty Images

A total of 34 products were approved in the first phase of the scheme — and distributed amongst 49 players, according to assistant vice president at ICRA Limited, Deepak Jotwani. 

“The first phase will result in reduction in imports from China by about 25-35% by 2029,” Jotwani estimated. 

India’s role in the pandemic

The government hopes to drive the pharmaceutical sector — currently valued at roughly $42 billion — up to $65 billion by 2024. Its goal is to double that target to between $120 billion to $130 billion by 2030.

India has also emerged as a key player in worldwide efforts to combat the pandemic. 

According to the government, India has supplied over 201 million doses to about 100 countries across Southeast Asia, South America, Europe, Africa and the Middle East as of May 9.

India has been exporting vaccines through both government-funded initiatives and under the Covax platform.

The country had to briefly stop exports in April 2021 when domestic cases surged and it needed more vaccines at home. It resumed exports in October that year.

Significantly, over 80% of the antiretroviral drugs used globally to combat AIDS are also supplied by Indian pharmaceutical firms, according to the government.

India was not always this dependent on China for essential ingredients for its drugs.

Reducing import dependence is important for reducing disruptions in India’s pharma supply chain.

Amitendu Palit

senior research fellow, Institute of South Asian Studies in NUS

In 1991, India imported only 1% of its APIs from China, according to PWC consulting group.

That changed when China ramped up API manufacturing in the 1990s across its 7,000 drug parks with infrastructure such as effluent treatment plants, subsidized power and water. Production costs in China fell sharply and drove Indian companies out of the API market.

Long road to self-sufficiency

It will be a “long time” before local production becomes large enough to satisfy the demand of India’s pharmaceutical producers, senior research fellow at the Institute of South Asian Studies at the National University of Singapore, Amitendu Palit told CNBC.

“Till then, India will need to import APIs substantially from China. Reducing import dependence is important for reducing disruptions in India’s pharma supply chain,” Palit said.

Founder of Mumbai-based Somerset Indus Capital Partners, which operates a private equity fund in health care, Mayur Sirdesai, said the production-linked incentive scheme’s focus could be narrower. 

“We will probably do better with low volume, by focusing on niche APIs than with high volume ones,” he said, adding that a lot of other chemical processes in the manufacturing cycle would also have to be moved to India to cut costs in the long run. 

Geopolitical considerations were behind the decision to reduce dependence on China, said Pavan Choudary, chairman and secretary general of the Medical Technology Association of India, a non-profit organization.

“Blind offshoring is now becoming ‘friendshoring,'” Choudary said, explaining “friendshoring″ to mean the outsourcing of business operations to countries that have a similar political system, and with whom there is a “history of peace”.

He also India was reflecting recent attempts by a number of countries to diversify supply chains away from China.

Choudary — an influential voice in shaping policy in the pharmaceutical industry — estimated that apart from APIs, India also imports $1.5 billion of medical equipment from China in imaging technology or machines to perform magnetic resonance imaging and other types of sophisticated scans.

He said reducing dependence on China for medical equipment would take longer than for APIs.

“APIs are dependent on a chemical ecosystem which already exists in India,” he said, adding that there was more “technological complexity” in medical devices. 

“It will take a little longer to cut this dependence,” he said.

Read original article here